From the publishers of JADPRO

CAR T-Cell Therapy Resource Center

Advertisement

Blood Advances

Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma

Pediatric Blood & Cancer

Neuropsychological functioning in pediatric patients with leukemia or lymphoma treated with CAR T-cell therapy: A retrospective chart review

Cancer Cell

Restoration of LAT activity improves CAR T cell sensitivity and persistence in response to antigen-low acute lymphoblastic leukemia

Journal of Clinical Oncology

Comparison of standard-of-care idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed/refractory multiple myeloma

Oncogene

Preclinical application of a CD155 targeting chimeric antigen receptor T-cell therapy for digestive system cancers

Brain

Current state and perspectives of CAR T-cell therapy in central nervous system diseases

Blood

CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML

Clinical Cancer Research

Phase I study of ROR1-specific CAR-T cells in advanced hematopoietic and epithelial malignancies

Leukemia

Anti-CD19 CAR-T cell therapy for acquired hemophilia A

Trends in Pharmacological Sciences

Boosting CAR-T cell therapy through vaccine synergy

International Immunopharmacology

The paths toward immunotherapy of esophageal cancer: An overview of clinical trials

Critical Reviews in Oncology/Hematology

Chimeric antigen receptor T cell immunotherapy for gynecological malignancies

Science Advances

Development of an antigen-based approach to noninvasively image CAR T cells in real time and as a predictive tool

Blood

Development of ALL-Hematotox (ALL-HT): Predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia

Blood Advances

Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network

Nature Medicine

Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma

Blood Advances

EASIX and m-EASIX predict CRS and ICANS in pediatric and AYA patients post CD19-CAR T cell therapy

Blood Advances

Access barriers to anti-CD19+ CAR T-cell therapy for NHL across a community transplant and cellular therapy network

Blood Advances

Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy

JAMA Network Open

Cardiovascular events after chimeric antigen receptor T-cell therapy for advanced hematologic malignant neoplasms: A meta-analysis

Blood Advances

Local radiation enhances systemic CAR T cell efficacy by augmenting antigen cross-presentation and T-cell infiltration

Blood Advances

Feasibility and favorable responses following investigational CAR T-Cell therapy for relapsed and refractory infant ALL

Bone Marrow Transplantation

Role of bridging RT in relapsed/refractory diffuse large B-cell lymphoma undergoing CAR-T therapy: A multicenter study

Frontiers in Immunology

Chimeric antigen receptor T-cell therapy in relapsed or refractory mantle cell lymphoma: A systematic review and meta-analysis

Blood Advances

Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma

Annals of Medicine

Comprehensive analysis of the efficacy and safety of CAR T-cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukemia: A systematic review and meta-analysis

Hematology

Successful treatment of two cases with Philadelphia-chromosome positive acute lymphoblastic leukemia who relapsed after allogeneic stem cell transplantation and the treatments with novel immunotherapies and ponatinib

Hematology

Procalcitonin level threshold and antibiotic use in patients receiving chimeric antigen receptor T-cell therapy

Human Vaccines & Immunotherapeutics

Approved CAR-T therapies have reproducible efficacy and safety in clinical practice

The Lancet

Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): An international, open-label, phase 2 trial

Blood

Optimizing the post-CAR T monitoring period for axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel

Blood

CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: A meta-analysis

New England Journal of Medicine Evidence

CD19 CAR T-cell therapy in autoimmune disease–A case series with follow-up

Blood Cancer Journal

Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission

The ASCO Post

Novel CAR T-cell therapy under study in relapsed or refractory non-Hodgkin lymphoma

New England Journal of Medicine Evidence

CAR T-cell immunotherapy in minority patients with lymphoma

The Lancet Oncology

Fractionated initial infusion and booster dose of ARI0002h, a humanised BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): A single-arm, multicentre academic pilot study

JAMA Network

CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome

New England Journal of Medicine

Cilta-cel or standard care in lenalidomide-refractory multiple myeloma

British Journal of Haematology

Severe persistent neurotoxicity associated with CAR T therapy in children

New England Journal of Medicine

Survival with axicabtagene ciloleucel in large B-cell lymphoma

Lancet

Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label single-arm, phase 1-2 study

British Journal of Haematology

Risk factors for CAR-T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan

ASGCT Abstract

First in human studies show activation of SC-DARIC33, a rapamycin-regulated anti-CD33 CAR T cell therapy, in patients with AML

Lancet

The denominator in early phase CAR T-cell trials examining novel taret antigens

British Journal of Haematology

Early lymphocyte collection for anti-CD19 CART production improves T-cell fitness in patients with relapsed/refractory diffuse large B-cell lymphoma

New England Journal of Medicine

GD2-CART01 for relapsed or refractory high-risk neuroblastoma

https://www.nejm.org/doi/full/10.1056/NEJMe2300317

Accompanying editorial for article: GD2-CART01 for relapsed or refractory high-risk neuroblastoma

Clinical Lymphoma, Myeloma, & Leukemia

SOHO State-of-the-art updates and next questions. BCMA-directed CAR T-cells: Early results and future directions

British Journal of Haematology

Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed/refractory solid organ transplant-related PTLD

Transplantation and Cellular Therapy

ASTCT, CIBMTR, and ESBMT Clinical Practice Recommendations for Transplantation and Cellular Therapies

https://www.nature.com/articles/s41591-022-02182-7

Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: Phase 1 UNIVERSAL trial interim results

British Journal of Haematology

CAR T in patients with large B-cell lymphoma not fit for autologous transplant

Clinical Lymphoma Myeloma & Leukemia

CAR T-cells for the treatment of refractory or relapsed large B-cell lymphoma: A single-center retrospective Canadian study

Journal of Clinical Oncology

Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: Results from the US Lymphoma CAR T Consortium

Journal of Clinical Oncology

Idecabtagene vicleucel for relapsed/refractory multiple myeloma: Real-world experience from the Myeloma CAR T Consortium

Expert Opinion on Drug Safety

Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma

Nature Medicine

A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy

AACR Meeting Abstract

CT023 - Phase 1 trial of CD19/CD20 bispecific chimeric antigen receptor-engineered naïve/memory T cells for relapsed or refractory non-Hodgkin lymphoma

AACR Meeting Abstract

CT011 - A phase 1 multicenter study (TRAVERSE) evaluating the safety and efficacy of ALLO-316 following conditioning regimen in pts with advanced or metastatic clear cell renal cell carcinoma (ccRCC)

Blood (2022 ASH Abstract)

Inflammatory Biomarker Clusters Are Predictive of Response and Toxicity in Large B-Cell Lymphoma Treated With CD19 CAR-T Cell Therapy

Blood (2022 ASH Abstract)

Analysis of 53 Patients With Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) Treated With CD7-Targeted CAR-T Cell Therapy

Blood (2022 ASH Abstract)

Observational Cohort Study of People Living with HIV (PWH) Treated with CD19-Directed CAR T Cell Therapy for B-Cell Lymphoid Malignancies—Interim Results of AIDS Malignancy Consortium (AMC) Study AMC-113

Blood (2022 ASH Abstract)

Targeting CNS Lymphoma with Intravenous Axicabtagene Ciloleucel: Evidence for Transcriptional Evolution Towards a Prominent Interferon Signature in CAR-T Cells Trafficking to the Tumor Site

MLN Matters

National Coverage Determination 110.24: Chimeric Antigen Receptor T-Cell Therapy

Blood

5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1)

BMS Press Release

Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi® (lisocabtagene maraleucel) Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

JAMA

“Off-the-Shelf” CAR T-Cell Therapy Tested in Pediatric B-Cell Leukemia

Blood (2022 ASH Abstract)

Interleukin-18 Secreting Autologous Anti-CD19 CAR T-Cells (huCART19-IL18) in Patients with Non-Hodgkin Lymphomas Relapsed or Refractory to Prior CAR T-Cell Therapy

Blood

Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy

Lancet Haematology

Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study

Journal of Clinical Oncology

Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial.

Blood

Interventions and outcomes of multiple myeloma patients receiving salvage treatment after BCMA-directed CAR T therapy

Lancet Haematology

UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial

Blood

Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation

Science Translational Medicine

Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia

Cancer Immunology Research

Hypophosphatemia Due to Increased Effector Cell Metabolic Activity is Associated with Neurotoxicity Symptoms in CD19-Targeted CAR T-cell Therapy

Transplantation and Cellular Therapy

Perspective: An International Fludarabine Shortage: Supply Chain Issues Impacting Transplantation and Immune Effector Cell Therapy Delivery

Journal of Clinical Oncology

Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia

Nature Medicine

Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma

New England Journal of Medicine

GPRC5D-Targeted CAR T Cells for Myeloma

The ASCO Post

High-Dose Chemotherapy and Stem Cell Transplant vs CAR T-Cell Therapy for Resistant DLBCL

Nature Medicine

Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy

CRISPR Therapeutics Press Release

CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell Lymphomas (CTCL)

Nature Medicine

Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus

JAMA Oncology

Assessment of Pretreatment and Posttreatment Evolution of Neurofilament Light Chain Levels in Patients Who Develop Immune Effector Cell–Associated Neurotoxicity Syndrome

Haematologica

ATRA works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T-cells

JAMA Network Open

Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma

Frontiers in Immunology

Comparable outcomes in patients with B-cell acute lymphoblastic leukemia receiving haploidentical hematopoietic stem cell transplantation

Lancet Oncology

New CAR T-cell therapy for solid tumours

Blood Cancer Discovery

Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma.

Blood Advances

Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy.

Blood Advances

Higher doses of tisagenlecleucel associate with improved outcomes: a report from the pediatric real-world CAR consortium.

Journal of Cancer Policy

Health-Related Quality of Life Data Collected in Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Clinical Trials

Blood

Response to SARS-CoV-2 Vaccination in Patients After Hematopoietic Cell Transplantation and CAR T-Cell Therapy

Nature Reviews Clinical Oncology

Preparing for CAR T Cell Therapy: Patient Selection, Bridging Therapies and Lymphodepletion

Expert Opinion on Investigational Drugs

CAR-T Cell Therapy for Triple-Negative Breast Cancer and Other Solid Tumors: Preclinical and Clinical Progress

Nature Medicine

Gut Microbiome Correlates of Response and Toxicity Following Anti-CD19 CAR T Cell Therapy

Transplantation and Cellular Therapy

Change in Neurocognitive Performance Among Patients With Non-Hodgkin’s Lymphoma in the First Year After CAR T-Cell Therapy

Blood Cancer Discovery

Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia

Biology of Blood and Marrow Transplantation

American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group Survey on Chimeric Antigen Receptor T Cell Therapy Administrative, Logistic, and Toxicity Management Practices in the United States

JAMA Oncology

Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome

Frontiers in Oncology

In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy

Transplantation and Cellular Therapy Journal

Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following CAR-T Cell Therapy: A Systematic Review

Journal of Oncology Pharmacy Practice

The Pharmacist’s Role in Chimeric Antigen Receptor T Cell Therapy

Biology of Blood and Marrow Transplantation

Implementation of an Oncology Nurse Practitioner Fellowship Program Focused on Adult Stem Transplant and Cellular Therapy Training

Molecular Cancer

Next Generation Chimeric Antigen Receptor T Cells: Safety Strategies to Overcome Toxicity

The ASCO Post

CAR T-Cell Therapy as Second-Line Treatment in Large B-Cell Lymphomas

Journal for ImmunoTherapy of Cancer

Perspectives on Outpatient Administration of CAR-T Cell Therapy in Aggressive B-Cell Lymphoma and Acute Lymphoblastic Leukemia

Radiology

Imaging-Based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy

Nature

Decade-Long Leukaemia Remissions With Persistence of CD4+ CAR T Cells

Blood Reviews

Current State and Next-Generation CAR-T Cells in Multiple Myeloma

The ASCO Post

POLARIX: Addition of Polatuzumab Vedotin-piiq to Standard of Care Significantly Reduces Progression of Diffuse Large B-Cell Lymphoma

Journal of Clinical Oncology

Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy

International Journal of Molecular Sciences

CAR T-Cell Therapy in Hematological Malignancies

BioDrugs

CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success

Stem Cell Research & Therapy

Novel CAR T Therapy is a Ray of Hope in the Treatment of Seriously Ill AML Patients

Blood Cancer Journal

CAR-T Cell Therapy: Current Limitations and Potential Strategies

2021 ASH Annual Meeting & Exposition

Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study

Journal of Geriatric Oncology

Real-World Adverse Events Associated With CAR T-Cell Therapy Among Adults Age ≥ 65 Years

Nature Reviews Clinical Oncology

Immunogenicity of CAR T Cells in Cancer Therapy

JAMA Oncology

SARS-CoV-2 Spike-Specific T-Cell Responses in Patients With B-Cell Depletion Who Received Chimeric Antigen Receptor T-Cell Treatments

2021 ASH Annual Meeting & Exposition

Primary Analysis of ZUMA‑7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard‑of‑Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Blood Adv

Optimal Fludarabine Lymphodepletion is Associated With Improved Outcomes Following CAR T-Cell Therapy

Chronic Dis Transl Med

Major Advances in the Treatment of Multiple Myeloma in American Society of Hematology Annual Meeting 2020

Clin Lymphoma Myeloma Leuk

CAR-T in B-Cell Lymphomas: The Past, Present, and Future

Oncol Ther

Patient Perspectives on Health-Related Quality of Life in Diffuse Large B-Cell Lymphoma Treated With CAR T-Cell Therapy: A Qualitative Study

Memo

CAR T Cell Therapy in Solid Tumors: A Short Review

Nature Communications

Biallelic Loss of BCMA as a Resistance Mechanism to CAR T Cell Therapy in a Patient With Multiple Myeloma

Annals of Clinical and Translational Neurology

Brain Dysfunction in COVID-19 and CAR-T Therapy: Cytokine Storm-Associated Encephalopathy

Frontiers in Immunology

Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia

Seminars in Oncology Nursing

Chimeric Antigen Receptor T-Cell Emergencies: Inpatient Administration, Assessment, and Management

Journal of the American College of Cardiology

Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy

The Cancer Journal

Chimeric Antigen Receptor T-Cell Therapeutics for Multiple Myeloma: Moving Into the Spotlight

Journal of Clinical Oncology

Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial

Infection

Recommendations for Screening, Monitoring, Prevention, and Prophylaxis of Infections in Adult and Pediatric Patients Receiving CAR T-Cell Therapy: A Position Paper

Nature Reviews Cancer

Recent Advances and Discoveries in the Mechanisms and Functions of CAR T Cells

Blood Advances

Infectious Complications in Relapsed Refractory Multiple Myeloma Patients After BCMA CAR T-Cell Therapy

Blood Advances

Comparison of 2-Year Outcomes With CAR T Cells (ZUMA-1) Versus Salvage Chemotherapy in Refractory Large B-Cell Lymphoma

Expert Review of Anti-Infective Therapy

CAR-T Cell Therapy and Infection: A Review

Biology of Blood and Marrow Transplantation

Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic

Journal of Blood Medicine

Assessing and Management of Neurotoxicity After CAR-T Therapy in Diffuse Large B-Cell Lymphoma

Nature Medicine

CAR T Cells With Dual Targeting of CD19 and CD22 in Adult Patients With Recurrent or Refractory B Cell Malignancies: A Phase 1 Trial

Blood Reviews

Recent Advances in CAR T-Cell Toxicity: Mechanisms, Manifestations and Management

The ASCO Post

Axicabtagene Ciloleucel Demonstrates Improvement Across Multiple Endpoints in Relapsed or Refractory Follicular Lymphoma

Hemasphere

In the Eye of the Storm: Immune-Mediated Toxicities Associated With CAR-T Cell Therapy

Nature Medicine

Antigen-Independent Activation Enhances The Efficacy of 4-1BB-Costimulated CD22 CAR T Cells

Journal for ImmunoTherapy of Cancer

Thrombopoietin Receptor Agonists for Acquired Thrombocytopenia Following Anti-CD19 CAR-T-Cell Therapy: A Case Report

Clinical Infectious Diseases

Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study

Frontiers in Oncology

New-Onset Severe Cytopenia After CAR-T Cell Therapy: Analysis of 76 Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

The Lancet

KTE-X19 for Relapsed or Refractory Adult B-Cell Acute Lymphoblastic Leukaemia: Phase 2 Results of the Single-Arm, Open-Label, Multicentre ZUMA-3 Study

Clinical Cancer Research

Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients With Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel

Journal of Cancer

Current Progress in CAR-T Cell Therapy for Hematological Malignancies

Nature Reviews Clinical Oncology

Engineering Strategies to Overcome the Current Roadblocks in CAR T Cell Therapy

Journal of the Advanced Practitioner in Oncology

CAR T-Cell Therapy: Adverse Events and Management

Journal of Clinical Oncology

Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma

The ASCO Post

Early-Phase Study Explores CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma

Cure

Novel CAR-T Cell Therapy Produces Early and Deep Responses in Certain Patients With Multiple Myeloma

Bloodless Medicine Management of a Patient Receiving CAR T-Cell Therapy

Transverse Myelitis With Paraplegia: An Atypical Manifestation of Neurotoxicity Following CAR T-Cell Therapy

CAR T-cell Infusion in an Outpatient Setting: An Ideal Option for Selected Patients When Available

Fast Facts #12: BCMA Targets